Topology-Programmed Peptide Architectures Orchestrate Durable Tumor Targeting and Cascade Antitumor Immunity
ACS Nano · 10.11.2026 · 20 (44) · 29963-29982
DOI: 10.1021/acsnano.6c13493 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 27.10.2026. Verfasst von Xiaowei Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Ministry of Industry and Information Technology, School of Chemistry and Ch…. Hauptthemen laut MEDLINE: Peptides, Antineoplastic Agents. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Natural Science Foundation of Hebei Province, Fundamental Research Funds for the Central Universities, Beijing Municipal Natural Science Foundation.
Abstract (Originalsprache)
Peptide supramolecular systems offer recognition and biocompatibility for precision theranostics, yet their in vivo performance is limited by insufficient structural stability, poor retention, and loss of accessible recognition interfaces under physiological perturbations. Herein, a topology-programmed supramolecular assembly strategy was developed to stabilize adaptive peptide architectures through confinement-guided organization. A β-sheet-based peptide EH, with PD-L1 (programmed death-ligand 1) targeting, favorable assembly behavior, and hydrophobic anchoring potential, was screened from an amphiphilic peptide library and integrated with immunoactivating SeAD quantum dots into PLGA (poly(lactic-co-glycolic acid)) microspheres featuring an interconnected hydrophobic channel network. This network guides channel-confined EH assembly through hydrophobic anchoring and β-sheet reinforcement, enabling ordered nanofiber alignment while preserving local conformational flexibility and exposed recognition motifs. This topology-programmed assembly converts dynamic peptide fibers into a structurally stabilized supramolecular interface, leading to prolonged tumor retention and sustained local immune checkpoint blockade. Meanwhile, ultrasound-activated SeAD induces immunogenic cell death and systemic antitumor immunity. By coupling confinement-stabilized peptide recognition with sonodynamic immune activation, EHSeAD@MS achieves durable local tumor intervention, immune microenvironment remodeling, and suppression of distant and metastatic lesions. It establishes a molecular design principle for balancing structural integrity and adaptive recognition in peptide supramolecules, providing a strategy for long-lasting peptide-based cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Ministry of Industry and Information Technology, School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing100081, P.…
- Beijing Kanghai Pharmaceutical Co., Ltd., Beijing102609, P. R. China.
ORCID-Profile: Liao Shen, Weizhi Wang
Förderung
- Natural Science Foundation of Hebei Province
- Fundamental Research Funds for the Central Universities
- Beijing Municipal Natural Science Foundation
- National Natural Science Foundation of China (NSFC)
Zitieren
APA
Zhang, X., Han, K., Li, N., Gao, S., Song, Y., Deng, J., Shen, L., & Wang, W. (2026). Topology-Programmed Peptide Architectures Orchestrate Durable Tumor Targeting and Cascade Antitumor Immunity. ACS Nano, 20(44), 29963-29982. https://doi.org/10.1021/acsnano.6c13493
Vancouver
Zhang X, Han K, Li N, Gao S, Song Y, Deng J, et al. Topology-Programmed Peptide Architectures Orchestrate Durable Tumor Targeting and Cascade Antitumor Immunity. ACS Nano. 2026;20(44):29963-29982. doi:10.1021/acsnano.6c13493
BibTeX
@article{Zhang2026,
author = {Zhang, Xiaowei and Han, Kai and Li, Naiqing and Gao, Shanqing and Song, Yufan and Deng, Jingrui and Shen, Liao and Wang, Weizhi},
title = {Topology-Programmed Peptide Architectures Orchestrate Durable Tumor Targeting and Cascade Antitumor Immunity},
journal = {ACS Nano},
year = {2026},
volume = {20},
number = {44},
pages = {29963--29982},
doi = {10.1021/acsnano.6c13493}
}
EUVIMED